Centanafadine demonstrates statistically significant and clinically relevant improvements in ADHD symptoms, supporting its potential as a new treatment option for attention-deficit/hyperactivity disorder.
Centanafadine demonstrated efficacy in a clinical trial for ADHD with comorbid anxiety, marking a significant development in the pharmacotherapy of attention-deficit/hyperactivity disorder.
Definium Therapeutics released Phase 3 results for its LSD-based treatment for depression, marking a significant clinical trial readout in psychedelic psychiatry.
A double-blind study demonstrates that low-dose amisulpride increases ventral striatum perfusion in MDD patients, providing mechanistic evidence for dopaminergic modulation of anhedonia.
This RCT demonstrates that adding modified cognitive stimulation therapy to standard pharmacotherapy (cholinesterase inhibitors/memantine) yields significant additional benefits in cognition and quality of life for mild-to-moderate Alzheimer's disease, with efficacy predicted by baseline education and lifestyle factors.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Jun 26)
- Consider centanafadine as a novel non-stimulant option for ADHD patients who have comorbid anxiety or cannot tolerate traditional stimulants.
- Review the clinical trial data for centanafadine to assess its potential efficacy in reducing core ADHD symptoms compared to standard of care.
- Recognize that low-dose amisulpride may offer a mechanistic approach to treating anhedonia in MDD by increasing ventral striatum perfusion via dopaminergic modulation.
- Monitor the evolving Phase 3 data for Definium Therapeutics' LSD-based treatment as it may expand the psychedelic psychiatry toolkit for depression.
- Incorporate modified cognitive stimulation therapy alongside standard pharmacotherapy (cholinesterase inhibitors/memantine) to enhance cognition and quality of life in mild-to-moderate Alzheimer's disease.
- Assess baseline education and lifestyle factors when prescribing adjunctive cognitive stimulation, as these may predict treatment efficacy in Alzheimer's patients.